Liezl Gambe

NobleOak Life (ASX:NOL) has provided an update on the potential impact of Victorian stamp duty reforms, following its April 3, 2025 announcement and disclosures in its FY25 financial accounts.

IperionX (ASX:IPX) has received the final US$4.6 million of a previously awarded US$47.1 million from the US Department of War.

Evolution Energy Minerals (ASX:EV) has recommenced soil sampling at its Chikundo Copper Project, located within the company's highly prospective Chilalo tenure in southern Tanzania.

CBH has confirmed it has not yet finalised a deal with US agribusiness giant Cargill to back a $500 million canola refinery in East Rockingham, amid speculation an agreement is imminent.

Rio Tinto (ASX:RIO) and Glencore are reportedly weighing a potential spin-off of selected assets, including coal, on the ASX as part of early-stage discussions around a mooted $300 billion mega-merger.

Neurocrine Biosciences (NASDAQ:NBIX) presented the first head-to-head imaging data on Thursday comparing the brain-binding potency of the two leading treatments for involuntary movement disorders.

The Goldman Sachs Group (NYSE:GS) reported fourth-quarter net income of $4.62 billion, or $14.01 per share, far outpacing Wall Street’s expectations as the firm capitalized on a "dealmaking renaissance" to close out 2025.

Arthur Hayes is positioning for a 2026 liquidity rebound by increasing exposure to Bitcoin-linked equities and Zcash.

Penumbra (NYSE:PEN), a global leader in thrombectomy technology, reported a surge in fourth-quarter revenue that exceeded its own raised forecasts, capping a year that will culminate in the company’s acquisition by Boston Scientific Corp. (NYSE:BSX).

First Horizon Corporation (NYSE:FHN) reported a substantial jump in its full-year 2025 results on Thursday, fueled by consistent execution in its core southern U.S. markets and a significant cleanup of its balance sheet.